Credit Suisse (SIX:CSGN) analyst Matt Miksic maintained a Buy rating on Abbott Laboratories (NYSE:ABT) on Sunday, setting a price target of $106, which is approximately 1.23% below the present share price of $107.32.
Miksic expects Abbott Laboratories to post earnings per share (EPS) of $0.30 for the fourth quarter of 2020.
The current consensus among 14 TipRanks analysts is for a Moderate Buy rating of shares in Abbott Labs, with an average price target of $118.75.
The analysts price targets range from a high of $136 to a low of $94.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $7.33 billion and a net profit of $672 million. The company's market cap is $194.14 billion.
According to TipRanks.com, Credit Suisse analyst Matt Miksic is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 10.5% and a 67.96% success rate.
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.